| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 10/22/2026 | ±2.5% | -0.9% | over-priced |
| 07/23/2026 | ±3.1% | -0.4% | over-priced |
| 04/23/2026 | ±2.1% | +2.6% | under-priced |
| 02/05/2026 | ±3.2% | +0.7% | over-priced |
| 10/23/2025 | ±3.0% | -0.5% | over-priced |
| 07/24/2025 | ±1.7% | -0.9% | over-priced |
| 04/24/2025 | ±2.3% | +0.5% | over-priced |
| 02/13/2025 | ±2.3% | +0.8% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | — | $443M | $213M |
| Q2 FY2026 | — | $435M | $217M |
| Q1 FY2026 | — | $429M | $215M |
| Q4 FY2025 | — | $425M | $206M |
VRSN (VRSN) reports in 85 days, with the next report estimated for 01/21/2027. Across the last 8 reports, options priced an average ±2.5% earnings move while the stock actually moved 0.9% on average — the market has systematically over-priced VRSN's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 5.7%. QuantLogix's live 5-factor engine currently reads VRSN as a buy at 89/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →